These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1347054)

  • 21. Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.
    Polonis VR; de Souza MS; Darden JM; Chantakulkij S; Chuenchitra T; Nitayaphan S; Brown AE; Robb ML; Birx DL
    J Virol; 2003 Aug; 77(15):8570-6. PubMed ID: 12857927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes.
    Zerhouni B; Nelson JA; Saha K
    J Virol; 2004 Feb; 78(3):1243-55. PubMed ID: 14722279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection.
    Nielsen C; Pedersen C; Lundgren JD; Gerstoft J
    AIDS; 1993 Aug; 7(8):1035-40. PubMed ID: 8104421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage.
    Xiao L; Owen SM; Goldman I; Lal AA; deJong JJ; Goudsmit J; Lal RB
    Virology; 1998 Jan; 240(1):83-92. PubMed ID: 9448692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection.
    van 't Wout AB; Blaak H; Ran LJ; Brouwer M; Kuiken C; Schuitemaker H
    J Virol; 1998 Jun; 72(6):5099-107. PubMed ID: 9573281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals.
    Llano A; Barretina J; Gutiérrez A; Blanco J; Cabrera C; Clotet B; Esté JA
    J Virol; 2001 Nov; 75(21):10319-25. PubMed ID: 11581400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype.
    Nakayama EE; Hoshino Y; Xin X; Liu H; Goto M; Watanabe N; Taguchi H; Hitani A; Kawana-Tachikawa A; Fukushima M; Yamada K; Sugiura W; Oka SI; Ajisawa A; Sato H; Takebe Y; Nakamura T; Nagai Y; Iwamoto A; Shioda T
    J Virol; 2000 Jun; 74(12):5452-9. PubMed ID: 10823849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
    Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
    AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus.
    Bozzette SA; McCutchan JA; Spector SA; Wright B; Richman DD
    J Infect Dis; 1993 Dec; 168(6):1374-9. PubMed ID: 7902382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection.
    Muñoz-Fernández MA; Obregón E; Navarro J; Börner C; Gurbindo MD; Sampelayo TH; Fernández-Cruz E
    Pediatr Res; 1996 Oct; 40(4):597-602. PubMed ID: 8888289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.
    Koot M; Schellekens PT; Mulder JW; Lange JM; Roos MT; Coutinho RA; Tersmette M; Miedema F
    J Infect Dis; 1993 Sep; 168(3):733-6. PubMed ID: 8102631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection.
    Koning FA; Kwa D; Boeser-Nunnink B; Dekker J; Vingerhoed J; Hiemstra H; Schuitemaker H
    J Infect Dis; 2003 Sep; 188(6):864-72. PubMed ID: 12964118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Replicative characteristics of primary isolates of the human immunodeficiency virus type 1 in peripheral blood mononuclear cells, primary macrophages and CD4+ transformed T-cell lines.
    Jolly PE
    Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1057-65. PubMed ID: 9449539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.
    De Wolf F; Hogervorst E; Goudsmit J; Fenyö EM; Rübsamen-Waigmann H; Holmes H; Galvao-Castro B; Karita E; Wasi C; Sempala SD
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1387-400. PubMed ID: 7888192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo.
    Llano A; Barretina J; Blanco J; Gutiérrez A; Clotet B; Esté JA
    AIDS; 2001 Sep; 15(14):1890-2. PubMed ID: 11579256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.
    Tersmette M; Gruters RA; de Wolf F; de Goede RE; Lange JM; Schellekens PT; Goudsmit J; Huisman HG; Miedema F
    J Virol; 1989 May; 63(5):2118-25. PubMed ID: 2564898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies.
    Mhashilkar AM; LaVecchio J; Eberhardt B; Porter-Brooks J; Boisot S; Dove JH; Pumphrey C; Li X; Weissmahr RN; Ring DB; Ramstedt U; Marasco WA
    Hum Gene Ther; 1999 Jun; 10(9):1453-67. PubMed ID: 10395371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus phenotype switching and disease progression in HIV-1 infection.
    Callaway DS; Ribeiro RM; Nowak MA
    Proc Biol Sci; 1999 Dec; 266(1437):2523-30. PubMed ID: 10693824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.
    Koot M; Vos AH; Keet RP; de Goede RE; Dercksen MW; Terpstra FG; Coutinho RA; Miedema F; Tersmette M
    AIDS; 1992 Jan; 6(1):49-54. PubMed ID: 1543566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.